stockrowRevvity Inc.
RVTY Healthcare Diagnostics & Research
Revvity Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 3.67% from fiscal 2024.
- Revenue
- +4.29%
- EPS
- +2.17%
- Free cash flow
- +27.0%
- Total debt
- −18.1%
Quarter to September 2026, against a year earlier
Follow RVTY
Alert me
Revvity Inc. (RVTY) Net income
Revvity Inc.'s net income for fiscal 2025 was $241.2M, down 10.8% from $270.4M in fiscal 2024. Over the twelve months to 30 September 2026 it was $253.2M. Over the past ten years it has ranged from $212.4M (fiscal 2015) to $943.2M (fiscal 2021); the current reading is higher than 45% of that period. Revvity Inc. ranks 13th of 49 Diagnostics & Research companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | $241.2M | (10.79%) |
| FY2024 | $270.4M | (60.99%) |
| FY2023 | $693.1M | 21.77% |
| FY2022 | $569.2M | (39.65%) |
| FY2021 | $943.2M | 29.57% |
| FY2020 | $727.9M | 219.87% |
| FY2019 | $227.6M | (4.36%) |
| FY2018 | $237.9M | (18.69%) |
| FY2017 | $292.6M | 24.90% |
| FY2016 | $234.3M | 10.30% |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | $62.3M | 20.22% |
| Jun 2026 | $51.8M | 27.27% |
| Mar 2026 | $40.7M | (58.60%) |
| Dec 2025 | $98.4M | 110.85% |
| 43 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| DGX Quest Diagnostics Incorporated compare | $1.2B |
| LH Labcorp Holdings Inc. compare | $1.0B |
| ILMN Illumina, Inc. compare | $895.0M |
| MEDP Medpace Holdings, Inc. compare | $517.8M |
| ICLR ICON PLC compare | $448.7M |
| QGEN QIAGEN N.V. compare | $409.3M |
| RVTY Revvity Inc. | $253.2M |
| CRL Charles River Laboratories International, Inc. compare | $42.6M |
| GH Guardant Health, Inc. compare | −$485.1M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on RVTY
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement